Summary
During the last 4 decades, gene therapy has moved from preclinical to clinical studies for many diseases ranging from monogenic recessive disorders such as hemophilia to more complex diseases such as cancer, cardiovascular disorders, and human immunodeficiency virus (HIV). To date, more than 1,340 gene therapy clinical trials have been completed, are ongoing, or have been approved in 28 countries, using more than 100 genes. Most of those clinical trials (66.5%) were aimed at the treatment of cancer. Early hype, failures, and tragic events have now largely been replaced by the necessary stepwise progress needed to realize clinical benefits. We now understand better the strengths and weaknesses of various gene transfer vectors; this facilitates the choice of appropriate vectors for individual diseases. Continuous advances in our understanding of tumor biology have allowed the development of elegant, more efficient, and less toxic treatment strategies. In this introductory chapter, we review the history of gene therapy since the early 1960s and present in detail two major recurring themes in gene therapy: (1) the development of vector and delivery systems and (2) the design of strategies to fight or cure particular diseases. The field of cancer gene therapy experienced an “awkward adolescence.” Although this field has certainly not yet reached maturity, it still holds the potential of alleviating the suffering of many individuals with cancer.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Notes
- 1.
The review material, findings, and conclusions in this book chapter have not been formally disseminated by the US Food and Drug Administration (FDA) and should not be construed to represent any Agency determination or policy.
References
Lederberg, J. (1963) Biological future of man. In: Wolstenholme, G., ed. Man and His Future. London: Churchill, 265.
Tatum, E. (1967) Molecular biology, nucleic acids, and the future of medicine. In: Lyght, C.E., ed. Reflections on Research and the Future of Medicine. New York: McGraw-Hill, 31–49.
Tatum, E. L. (1966) Molecular biology, nucleic acids, and the future of medicine. Perspect. Biol. Med. 10, 19–32.
Lederberg, J. (1966) Experimental genetics and human evolution. Am. Naturalist 100, 519–531.
Burnet, M. (1971) Genes, Dreams and Reality. New York: Basic Books. 71.
Culliton, B. J. (1989) French Anderson's 20-year crusade. Science 246, 748.
Nirenberg, M. W. (1967) Will society be prepared? Science 157, 633.
Sinsheimer, R. (1969) The prospect for designed genetic change. Am. Sci. 57, 134–142.
Terheggen, H., Schwenk, A., Van Sande, M., Lowenthal, A., and Columbo, J. (1969) Argininemia with arginase deficiency. Lancet 2, 748–749.
Rogers, S. (1966) Shope papilloma virus: a passenger in man and its significance to the potential control of the host genome. Nature 212, 1220–1222.
Meselson, M., and Yuan, R. (1968) DNA restriction enzyme from E. coli. Nature 217, 1110–1114.
Kelly, T. J., Jr., and Smith, H. O. (1970) A restriction enzyme from Hemophilus influenzae. II. J. Mol. Biol. 51, 393–409.
Smith, H. O., and Wilcox, K. W. (1970) A restriction enzyme from Hemophilus influenzae. I. Purification and general properties. J. Mol. Biol. 51, 379–391.
Danna, K., and Nathans, D. (1971) Specific cleavage of simian virus 40 DNA by restriction endonuclease of Hemophilus influenzae. Proc. Natl. Acad. Sci. USA 68, 2913–2917.
Wigler, M., Silverstein, S., Lee, L. S., Pellicer, A., Cheng, Y., and Axel, R. (1977) Transfer of purified herpes virus thymidine kinase gene to cultured mouse cells. Cell 11, 223–232.
Anderson, W. F., Killos, L., Sanders-Haigh, L., Kretschmer, P. J., and Diacumakos, E. G. (1980) Replication and expression of thymidine kinase and human globin genes microinjected into mouse fibroblasts. Proc. Natl. Acad. Sci. USA 77, 5399–5403.
Anderson, W. F., and Fletcher, J. C. (1980) Sounding boards. Gene therapy in human beings: when is it ethical to begin? N. Engl. J. Med. 303, 1293–1297.
Miller, A. D., Jolly, D. J., Friedmann, T., and Verma, I. M. (1983) A transmissible retrovirus expressing human hypoxanthine phosphoribosyltransferase (HPRT): gene transfer into cells obtained from humans deficient in HPRT. Proc. Natl. Acad. Sci. USA 80, 4709–4713.
Willis, R. C., Jolly, D. J., Miller, A. D., Plent, M. M., Esty, A. C., Anderson, P. J., Chang, H. C., Jones, O. W., Seegmiller, J. E., and Friedmann, T. (1984) Partial phenotypic correction of human Lesch-Nyhan (hypoxanthine-guanine phosphoribosyltransferase-deficient) lymphoblasts with a transmissible retroviral vector. J. Biol. Chem. 259, 7842–7849.
Joyner, A., Keller, G., Phillips, R. A., and Bernstein, A. (1983) Retrovirus transfer of a bacterial gene into mouse haematopoietic progenitor cells. Nature 305, 556–558.
Watanabe, S., and Temin, H. M. (1983) Construction of a helper cell line for avian reticuloendotheliosis virus cloning vectors. Mol. Cell. Biol. 3, 2241–2249.
Mann, R., Mulligan, R. C., and Baltimore, D. (1983) Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus. Cell 33, 153–159.
Williams, D. A., Lemischka, I. R., Nathan, D. G., and Mulligan, R. C. (1984) Introduction of new genetic material into pluripotent haematopoietic stem cells of the mouse. Nature 310, 476–480.
Van Doren, K., Hanahan, D., and Gluzman, Y. (1984) Infection of eukaryotic cells by helper-independent recombinant adenoviruses: early region 1 is not obligatory for integration of viral DNA. J. Virol. 50, 606–614.
Hermonat, P. L., and Muzyczka, N. (1984) Use of adeno-associated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells. Proc. Natl. Acad. Sci. USA 81, 6466–6470.
Tratschin, J. D., West, M. H., Sandbank, T., and Carter, B. J. (1984) A human parvovirus, adeno-associated virus, as a eukaryotic vector: transient expression and encapsidation of the prokaryotic gene for chloramphenicol acetyltransferase. Mol. Cell. Biol. 4, 2072–2081.
Eglitis, M. A., Kantoff, P., Gilboa, E., and Anderson, W. F. (1985) Gene expression in mice after high efficiency retroviral-mediated gene transfer. Science 230, 1395–1398.
Rosenberg, S. A., Aebersold, P., Cornetta, K., Kasid, A., Morgan, R. A., Moen, R., Karson, E. M., Lotze, M. T., Yang, J. C., Topalian, S. L., et al. (1990) Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N. Engl. J. Med. 323, 570–578.
Blaese, R. M., Culver, K. W., Miller, A. D., Carter, C. S., Fleisher, T., Clerici, M., Shearer, G., Chang, L., Chiang, Y., Tolstoshev, P., Greenblatt, J. J., Rosenberg, S. A., Klein, H., Berger, M., Mullen, C. A., Ramsey, W. J., Muul, L., Morgan, R. A., and Anderson, W. F. (1995) T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years. Science 270, 475–480.
Wilson, J. M., Grossman, M., Raper, S. E., Baker, J. R., Jr., Newton, R. S., and Thoene, J. G. (1992) Ex vivo gene therapy of familial hypercholesterolemia. Hum. Gene Ther. 3, 179–222.
Grossman, M., Raper, S. E., Kozarsky, K., Stein, E. A., Engelhardt, J. F., Muller, D., Lupien, P. J., and Wilson, J. M. (1994) Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia. Nat. Genet. 6, 335–341.
Grossman, M., Rader, D. J., Muller, D. W., Kolansky, D. M., Kozarsky, K., Clark, B. J., 3rd, Stein, E. A., Lupien, P. J., Brewer, H. B., Jr., Raper, S. E., et al. (1995) A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nat. Med. 1, 1148–1154.
Cavazzana-Calvo, M., Hacein-Bey, S., de Saint Basile, G., Gross, F., Yvon, E., Nusbaum, P., Selz, F., Hue, C., Certain, S., Casanova, J. L., Bousso, P., Deist, F. L., and Fischer, A. (2000) Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288, 669–672.
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., Sorensen, R., Forster, A., Fraser, P., Cohen, J. I., de Saint Basile, G., Alexander, I., Wintergerst, U., Frebourg, T., Aurias, A., Stoppa-Lyonnet, D., Romana, S., Radford-Weiss, I., Gross, F., Valensi, F., Delabesse, E., Macintyre, E., Sigaux, F., Soulier, J., Leiva, L. E., Wissler, M., Prinz, C., Rabbitts, T. H., Le Deist, F., Fischer, A., and Cavazzana-Calvo, M. (2003) LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302, 415–419.
Nienhuis, A. W., Dunbar, C. E., and Sorrentino, B. P. (2006) Genotoxicity of retroviral integration in hematopoietic cells. Mol. Ther. 13, 1031–1049.
Bester, A. C., Schwartz, M., Schmidt, M., Garrigue, A., Hacein-Bey-Abina, S., Cavazzana-Calvo, M., Ben-Porat, N., Von Kalle, C., Fischer, A., and Kerem, B. (2006) Fragile sites are preferential targets for integrations of MLV vectors in gene therapy. Gene Ther. 13, 1057–1059.
Dave, U. P., Jenkins, N. A., and Copeland, N. G. (2004) Gene therapy insertional mutagenesis insights. Science 303, 333.
Aiuti, A., Slavin, S., Aker, M., Ficara, F., Deola, S., Mortellaro, A., Morecki, S., Andolfi, G., Tabucchi, A., Carlucci, F., Marinello, E., Cattaneo, F., Vai, S., Servida, P., Miniero, R., Roncarolo, M. G., and Bordignon, C. (2002) Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 296, 2410–2413.
Gaspar, H. B., Bjorkegren, E., Parsley, K., Gilmour, K. C., King, D., Sinclair, J., Zhang, F., Giannakopoulos, A., Adams, S., Fairbanks, L. D., Gaspar, J., Henderson, L., Xu-Bayford, J. H., Davies, E. G., Veys, P. A., Kinnon, C., and Thrasher, A. J. (2006) Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning. Mol. Ther. 14, 505–513.
Rainov, N. G. (2000) A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum. Gene Ther. 11, 2389–2401.
Khuri, F. R., Nemunaitis, J., Ganly, I., Arseneau, J., Tannock, I. F., Romel, L., Gore, M., Ironside, J., MacDougall, R. H., Heise, C., Randlev, B., Gillenwater, A. M., Bruso, P., Kaye, S. B., Hong, W. K., and Kirn, D. H. (2000) a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med. 6, 879–885.
Alton, E. (2007) Progress and prospects: gene therapy clinical trials (part 1). Gene Ther. 14, 1439–1447.
Griesenbach, U. (2007) Progress and prospects: gene therapy clinical trials (part 2). Gene Ther. 14, 1555–1563.
Edelstein, M. L., Abedi, M. R., and Wixon, J. (2007) Gene therapy clinical trials worldwide to 2007--an update. J. Gene Med. 9, 833–842.
Berns, A. (2004) Good news for gene therapy. N. Engl. J. Med. 350, 1679–1680.
Aghi, M., Hochberg, F., and Breakefield, X. O. (2000) Prodrug activation enzymes in cancer gene therapy. J. Gene Med. 2, 148–164.
Rux, J. J., and Burnett, R. M. (2004) Adenovirus structure. Hum. Gene Ther. 15, 1167–1176.
Majhen, D., and Ambriovic-Ristov, A. (2006) Adenoviral vectors – how to use them in cancer gene therapy? Virus Res. 119, 121–133.
Xia, D., Henry, L. J., Gerard, R. D., and Deisenhofer, J. (1994) Crystal structure of the receptor-binding domain of adenovirus type 5 fiber protein at 1.7 A resolution. Structure 2, 1259–1270.
Bergelson, J. M., Cunningham, J. A., Droguett, G., Kurt-Jones, E. A., Krithivas, A., Hong, J. S., Horwitz, M. S., Crowell, R. L., and Finberg, R. W. (1997) Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 275, 1320–1323.
Li, J., Lad, S., Yang, G., Luo, Y., Iacobelli-Martinez, M., Primus, F. J., Reisfeld, R. A., and Li, E. (2006) Adenovirus fiber shaft contains a trimerization element that supports peptide fusion for targeted gene delivery. J. Virol. 80, 12324–12331.
Meier, O., Boucke, K., Hammer, S. V., Keller, S., Stidwill, R. P., Hemmi, S., and Greber, U. F. (2002) Adenovirus triggers macropinocytosis and endosomal leakage together with its clathrin-mediated uptake. J. Cell. Biol. 158, 1119–1131.
Young, L. S., Searle, P. F., Onion, D., and Mautner, V. (2006) Viral gene therapy strategies: from basic science to clinical application. J. Pathol. 208, 299–318.
Bischoff, J. R., Kirn, D. H., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., Nye, J. A., Sampson-Johannes, A., Fattaey, A., and McCormick, F. (1996) An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274, 373–376.
Heise, C., Hermiston, T., Johnson, L., Brooks, G., Sampson-Johannes, A., Williams, A., Hawkins, L., and Kirn, D. (2000) An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat. Med. 6, 1134–1139.
Fukuda, K., Abei, M., Ugai, H., Seo, E., Wakayama, M., Murata, T., Todoroki, T., Tanaka, N., Hamada, H., and Yokoyama, K. K. (2003) E1A, E1B double-restricted adenovirus for oncolytic gene therapy of gallbladder cancer. Cancer Res. 63, 4434–4440.
Balague, C., Noya, F., Alemany, R., Chow, L. T., and Curiel, D. T. (2001) Human papillomavirus E6E7-mediated adenovirus cell killing: selectivity of mutant adenovirus replication in organotypic cultures of human keratinocytes. J. Virol. 75, 7602–7611.
Ali, H., LeRoy, G., Bridge, G., and Flint, S. J. (2007) The adenovirus L4 33-kilodalton protein binds to intragenic sequences of the major late promoter required for late phase-specific stimulation of transcription. J. Virol. 81, 1327–1338.
Kaplan, J. M. (2005) Adenovirus-based cancer gene therapy. Curr. Gene Ther. 5, 595–605.
Flint, J., and Shenk, T. (1997) Viral transactivating proteins. Annu. Rev. Genet. 31, 177–212.
Yew, P. R., and Berk, A. J. (1992) Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein. Nature 357, 82–85.
Mizuguchi, H., and Hayakawa, T. (2004) Targeted adenovirus vectors. Hum. Gene Ther. 15, 1034–1044.
Raper, S. E., Chirmule, N., Lee, F. S., Wivel, N. A., Bagg, A., Gao, G. P., Wilson, J. M., and Batshaw, M. L. (2003) Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol. Genet. Metab. 80, 148–158.
Bett, A. J., Haddara, W., Prevec, L., and Graham, F. L. (1994) An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc. Natl. Acad. Sci. USA 91, 8802–8806.
Schaack, J. (2005) Adenovirus vectors deleted for genes essential for viral DNA replication. Front Biosci. 10, 1146–1155.
Yang, Y., Nunes, F. A., Berencsi, K., Furth, E. E., Gonczol, E., and Wilson, J. M. (1994) Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc. Natl. Acad. Sci. USA 91, 4407–4411.
Knowles, M. R., Hohneker, K. W., Zhou, Z., Olsen, J. C., Noah, T. L., Hu, P. C., Leigh, M. W., Engelhardt, J. F., Edwards, L. J., Jones, K. R., and et al. (1995) A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. N. Engl. J. Med. 333, 823–831.
Amalfitano, A., Hauser, M. A., Hu, H., Serra, D., Begy, C. R., and Chamberlain, J. S. (1998) Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted. J. Virol. 72, 926–933.
Gorziglia, M. I., Lapcevich, C., Roy, S., Kang, Q., Kadan, M., Wu, V., Pechan, P., and Kaleko, M. (1999) Generation of an adenovirus vector lacking E1, e2a, E3, and all of E4 except open reading frame 3. J. Virol. 73, 6048–6055.
Ji, L., Bouvet, M., Price, R. E., Roth, J. A., and Fang, B. (1999) Reduced toxicity, attenuated immunogenicity and efficient mediation of human p53 gene expression in vivo by an adenovirus vector with deleted E1-E3 and inactivated E4 by GAL4-TATA promoter replacement. Gene Ther. 6, 393–402.
Lieber, A., Steinwaerder, D. S., Carlson, C. A., and Kay, M. A. (1999) Integrating adenovirus-adeno-associated virus hybrid vectors devoid of all viral genes. J. Virol. 73, 9314–9324.
Steinwaerder, D. S., Carlson, C. A., and Lieber, A. (1999) Generation of adenovirus vectors devoid of all viral genes by recombination between inverted repeats. J. Virol. 73, 9303–9313.
Schiedner, G., Morral, N., Parks, R. J., Wu, Y., Koopmans, S. C., Langston, C., Graham, F. L., Beaudet, A. L., and Kochanek, S. (1998) Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat. Genet. 18, 180–183.
Gall, J., Kass-Eisler, A., Leinwand, L., and Falck-Pedersen, E. (1996) Adenovirus type 5 and 7 capsid chimera: fiber replacement alters receptor tropism without affecting primary immune neutralization epitopes. J. Virol. 70, 2116–2123.
Chillon, M., Bosch, A., Zabner, J., Law, L., Armentano, D., Welsh, M. J., and Davidson, B. L. (1999) Group D adenoviruses infect primary central nervous system cells more efficiently than those from group C. J. Virol. 73, 2537–2540.
Shayakhmetov, D. M., Papayannopoulou, T., Stamatoyannopoulos, G., and Lieber, A. (2000) Efficient gene transfer into human CD34(+) cells by a retargeted adenovirus vector. J. Virol. 74, 2567–2583.
Denby, L., Work, L. M., Graham, D., Hsu, C., von Seggern, D. J., Nicklin, S. A., and Baker, A. H. (2004) Adenoviral serotype 5 vectors pseudotyped with fibers from subgroup D show modified tropism in vitro and in vivo. Hum. Gene Ther. 15, 1054–1064.
Suominen, E., Toivonen, R., Grenman, R., and Savontaus, M. (2006) Head and neck cancer cells are efficiently infected by Ad5/35 hybrid virus. J. Gene Med. 8, 1223–1231.
Denby, L., Work, L. M., Seggern, D. J., Wu, E., McVey, J. H., Nicklin, S. A., and Baker, A. H. (2007) Development of renal-targeted vectors through combined in vivo phage display and capsid engineering of adenoviral fibers from serotype 19p. Mol. Ther. 15, 1647–1654.
Wickham, T. J., Tzeng, E., Shears, L. L., 2nd, Roelvink, P. W., Li, Y., Lee, G. M., Brough, D. E., Lizonova, A., and Kovesdi, I. (1997) Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J. Virol. 71, 8221–8229.
Hemminki, A., Kanerva, A., Liu, B., Wang, M., Alvarez, R. D., Siegal, G. P., and Curiel, D. T. (2003) Modulation of coxsackie-adenovirus receptor expression for increased adenoviral transgene expression. Cancer Res. 63, 847–853.
Vincent, T., Pettersson, R. F., Crystal, R. G., and Leopold, P. L. (2004) Cytokine-mediated downregulation of coxsackievirus-adenovirus receptor in endothelial cells. J. Virol. 78, 8047–8058.
Oh, I. K., Mok, H., and Park, T. G. (2006) Folate immobilized and PEGylated adenovirus for retargeting to tumor cells. Bioconjug. Chem. 17, 721–727.
Leamon, C. P., and Low, P. S. (1991) Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis. Proc. Natl. Acad. Sci. USA 88, 5572–5576.
Paillart, J. C., Shehu-Xhilaga, M., Marquet, R., and Mak, J. (2004) Dimerization of retroviral RNA genomes: an inseparable pair. Nat. Rev. Microbiol. 2, 461–472.
Andrake, M. D., and Skalka, A. M. (1996) Retroviral integrase, putting the pieces together. J. Biol. Chem. 271, 19633–19636.
Khan, E., Mack, J. P., Katz, R. A., Kulkosky, J., and Skalka, A. M. (1991) Retroviral integrase domains: DNA binding and the recognition of LTR sequences. Nucleic Acids Res. 19, 851–860.
Balvay, L., Lopez Lastra, M., Sargueil, B., Darlix, J. L., and Ohlmann, T. (2007) Translational control of retroviruses. Nat. Rev. Microbiol. 5, 128–140.
Bender, W., Chien, Y. H., Chattopadhyay, S., Vogt, P. K., Gardner, M. B., and Davidson, N. (1978) High-molecular-weight RNAs of AKR, NZB, and wild mouse viruses and avian reticuloendotheliosis virus all have similar dimer structures. J. Virol. 25, 888–896.
Goff, S. P., and Lobel, L. I. (1987) Mutants of murine leukemia viruses and retroviral replication. Biochim. Biophys. Acta 907, 93–123.
Miller, A. D. (1996) Cell-surface receptors for retroviruses and implications for gene transfer. Proc. Natl. Acad. Sci. USA 93, 11407–11413.
White, J. M. (1992) Membrane fusion. Science 258, 917–924.
Thomas, C. E., Ehrhardt, A., and Kay, M. A. (2003) Progress and problems with the use of viral vectors for gene therapy. Nat. Rev. Genet. 4, 346–358.
Yi, Y., Hahm, S. H., and Lee, K. H. (2005) Retroviral gene therapy: safety issues and possible solutions. Curr. Gene Ther. 5, 25–35.
Xu, L., Mei, M., Haskins, M. E., Nichols, T. C., O'Donnell, P., Cullen, K., Dillow, A., Bellinger, D., and Ponder, K. P. (2007) Immune response after neonatal transfer of a human factor IX-expressing retroviral vector in dogs, cats, and mice. Thromb. Res. 120, 269–280.
Li, Z., Kustikova, O. S., Kamino, K., Neumann, T., Rhein, M., Grassman, E., Fehse, B., and Baum, C. (2007) Insertional mutagenesis by replication-deficient retroviral vectors encoding the large T oncogene. Ann. N Y Acad. Sci. 1106, 95–113.
Rodrigues, T., Carvalho, A., Carmo, M., Carrondo, M. J., Alves, P. M., and Cruz, P. E. (2007) Scaleable purification process for gene therapy retroviral vectors. J. Gene Med. 9, 233–243.
Weber, E., Anderson, W. F., and Kasahara, N. (2001) Recent advances in retrovirus vector-mediated gene therapy: teaching an old vector new tricks. Curr. Opin. Mol. Ther. 3, 439–453.
Sinn, P. L., Sauter, S. L., and McCray, P. B., Jr. (2005) Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors – design, biosafety, and production. Gene Ther. 12, 1089–1098.
Kaiser, J. (2003) Gene therapy. Seeking the cause of induced leukemias in X-SCID trial. Science 299, 495.
Maxfield, L. F., Fraize, C. D., and Coffin, J. M. (2005) Relationship between retroviral DNA-integration-site selection and host cell transcription. Proc. Natl. Acad. Sci. USA 102, 1436–1441.
Tan, W., Zhu, K., Segal, D. J., Barbas, C. F., 3rd, and Chow, S. A. (2004) Fusion proteins consisting of human immunodeficiency virus type 1 integrase and the designed polydactyl zinc finger protein E2C direct integration of viral DNA into specific sites. J. Virol. 78, 1301–1313.
Ellis, J., and Yao, S. (2005) Retrovirus silencing and vector design: relevance to normal and cancer stem cells? Curr. Gene Ther. 5, 367–373.
Wei, G. H., Liu, D. P., and Liang, C. C. (2005) Chromatin domain boundaries: insulators and beyond. Cell Res. 15, 292–300.
Dalba, C., Klatzmann, D., Logg, C. R., and Kasahara, N. (2005) Beyond oncolytic virotherapy: replication-competent retrovirus vectors for selective and stable transduction of tumors. Curr. Gene Ther. 5, 655–667.
Wang, W. J., Tai, C. K., Kasahara, N., and Chen, T. C. (2003) Highly efficient and tumor-restricted gene transfer to malignant gliomas by replication-competent retroviral vectors. Hum. Gene Ther. 14, 117–127.
Wang, W., Tai, C. K., Kershaw, A. D., Solly, S. K., Klatzmann, D., Kasahara, N., and Chen, T. C. (2006) Use of replication-competent retroviral vectors in an immunocompetent intracranial glioma model. Neurosurg. Focus 20, E25.
Solly, S. K., Trajcevski, S., Frisen, C., Holzer, G. W., Nelson, E., Clerc, B., Abordo-Adesida, E., Castro, M., Lowenstein, P., and Klatzmann, D. (2003) Replicative retroviral vectors for cancer gene therapy. Cancer Gene Ther. 10, 30–39.
Hiraoka, K., Kimura, T., Logg, C. R., Tai, C. K., Haga, K., Lawson, G. W., and Kasahara, N. (2007) Therapeutic efficacy of replication-competent retrovirus vector-mediated suicide gene therapy in a multifocal colorectal cancer metastasis model. Cancer Res. 67, 5345–5353.
Li, Z., Dullmann, J., Schiedlmeier, B., Schmidt, M., von Kalle, C., Meyer, J., Forster, M., Stocking, C., Wahlers, A., Frank, O., Ostertag, W., Kuhlcke, K., Eckert, H. G., Fehse, B., and Baum, C. (2002) Murine leukemia induced by retroviral gene marking. Science 296, 497.
Donahue, R. E., Kessler, S. W., Bodine, D., McDonagh, K., Dunbar, C., Goodman, S., Agricola, B., Byrne, E., Raffeld, M., Moen, R., and et al. (1992) Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer. J. Exp. Med. 176, 1125–1135.
Mitrophanous, K., Yoon, S., Rohll, J., Patil, D., Wilkes, F., Kim, V., Kingsman, S., Kingsman, A., and Mazarakis, N. (1999) Stable gene transfer to the nervous system using a non-primate lentiviral vector. Gene Ther. 6, 1808–1818.
Poeschla, E. M., Wong-Staal, F., and Looney, D. J. (1998) Efficient transduction of nondividing human cells by feline immunodeficiency virus lentiviral vectors. Nat. Med. 4, 354–357.
Wiznerowicz, M., and Trono, D. (2005) Harnessing HIV for therapy, basic research and biotechnology. Trends Biotechnol. 23, 42–47.
Naldini, L., Blomer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F. H., Verma, I. M., and Trono, D. (1996) In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272, 263–267.
Lewis, P., Hensel, M., and Emerman, M. (1992) Human immunodeficiency virus infection of cells arrested in the cell cycle. EMBO J. 11, 3053–3058.
Blomer, U., Naldini, L., Kafri, T., Trono, D., Verma, I. M., and Gage, F. H. (1997) Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector. J. Virol. 71, 6641–6649.
Miyoshi, H., Takahashi, M., Gage, F. H., and Verma, I. M. (1997) Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector. Proc. Natl. Acad. Sci. USA 94, 10319–10323.
Kafri, T. (2004) Gene delivery by lentivirus vectors an overview. Methods Mol. Biol. 246, 367–390.
Mazarakis, N. D., Azzouz, M., Rohll, J. B., Ellard, F. M., Wilkes, F. J., Olsen, A. L., Carter, E. E., Barber, R. D., Baban, D. F., Kingsman, S. M., Kingsman, A. J., O'Malley, K., and Mitrophanous, K. A. (2001) Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery. Hum. Mol. Genet. 10, 2109–2121.
Wong, L. F., Azzouz, M., Walmsley, L. E., Askham, Z., Wilkes, F. J., Mitrophanous, K. A., Kingsman, S. M., and Mazarakis, N. D. (2004) Transduction patterns of pseudotyped lentiviral vectors in the nervous system. Mol. Ther. 9, 101–111.
Deglon, N., Tseng, J. L., Bensadoun, J. C., Zurn, A. D., Arsenijevic, Y., Pereira de Almeida, L., Zufferey, R., Trono, D., and Aebischer, P. (2000) Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system in Parkinson's disease. Hum. Gene Ther. 11, 179–190.
Han, J. J., Mhatre, A. N., Wareing, M., Pettis, R., Gao, W. Q., Zufferey, R. N., Trono, D., and Lalwani, A. K. (1999) Transgene expression in the guinea pig cochlea mediated by a lentivirus-derived gene transfer vector. Hum. Gene Ther. 10, 1867–1873.
Miyoshi, H., Blomer, U., Takahashi, M., Gage, F. H., and Verma, I. M. (1998) Development of a self-inactivating lentivirus vector. J. Virol. 72, 8150–8157.
Pan, D., Gunther, R., Duan, W., Wendell, S., Kaemmerer, W., Kafri, T., Verma, I. M., and Whitley, C. B. (2002) Biodistribution and toxicity studies of VSVG-pseudotyped lentiviral vector after intravenous administration in mice with the observation of in vivo transduction of bone marrow. Mol. Ther. 6, 19–29.
Vigna, E., and Naldini, L. (2000) Lentiviral vectors: excellent tools for experimental gene transfer and promising candidates for gene therapy. J. Gene Med. 2, 308–316.
Jakobsson, J., and Lundberg, C. (2006) Lentiviral vectors for use in the central nervous system. Mol. Ther. 13, 484–493.
Dull, T., Zufferey, R., Kelly, M., Mandel, R. J., Nguyen, M., Trono, D., and Naldini, L. (1998) A third-generation lentivirus vector with a conditional packaging system. J. Virol. 72, 8463–8471.
Kim, V. N., Mitrophanous, K., Kingsman, S. M., and Kingsman, A. J. (1998) Minimal requirement for a lentivirus vector based on human immunodeficiency virus type 1. J. Virol. 72, 811–816.
Kotsopoulou, E., Kim, V. N., Kingsman, A. J., Kingsman, S. M., and Mitrophanous, K. A. (2000) A Rev-independent human immunodeficiency virus type 1 (HIV-1)-based vector that exploits a codon-optimized HIV-1 gag-pol gene. J. Virol. 74, 4839–4852.
Rohll, J. B., Mitrophanous, K. A., Martin-Rendon, E., Ellard, F. M., Radcliffe, P. A., Mazarakis, N. D., and Kingsman, S. M. (2002) Design, production, safety, evaluation, and clinical applications of nonprimate lentiviral vectors. Methods Enzymol. 346, 466–500.
Sirin, O., and Park, F. (2003) Regulating gene expression using self-inactivating lentiviral vectors containing the mifepristone-inducible system. Gene 323, 67–77.
Reiser, J., Lai, Z., Zhang, X. Y., and Brady, R. O. (2000) Development of multigene and regulated lentivirus vectors. J. Virol. 74, 10589–10599.
Ralph, G. S., Binley, K., Wong, L. F., Azzouz, M., and Mazarakis, N. D. (2006) Gene therapy for neurodegenerative and ocular diseases using lentiviral vectors. Clin. Sci. (Lond) 110, 37–46.
Krisky, D. M., Marconi, P. C., Oligino, T. J., Rouse, R. J., Fink, D. J., Cohen, J. B., Watkins, S. C., and Glorioso, J. C. (1998) Development of herpes simplex virus replication-defective multigene vectors for combination gene therapy applications. Gene Ther. 5, 1517–1530.
Glorioso, J. C., and Fink, D. J. (2004) Herpes vector-mediated gene transfer in treatment of diseases of the nervous system. Annu. Rev. Microbiol. 58, 253–271.
Latchman, D. S. (1999) Herpes simplex virus vectors for gene therapy in Parkinson's disease and other diseases of the nervous system. J. R. Soc. Med. 92, 566–570.
Kristensson, K., Lycke, E., and Sjostrand, J. (1971) Spread of herpes simplex virus in peripheral nerves. Acta Neuropathol. (Berl) 17, 44–53.
Berges, B. K., Wolfe, J. H., and Fraser, N. W. (2007) Transduction of brain by herpes simplex virus vectors. Mol. Ther. 15, 20–29.
Burton, E. A., and Glorioso, J. C. (2001) Multi-modal combination gene therapy for malignant glioma using replication-defective HSV vectors. Drug Discov. Today 6, 347–356.
Yenari, M. A., Fink, S. L., Sun, G. H., Chang, L. K., Patel, M. K., Kunis, D. M., Onley, D., Ho, D. Y., Sapolsky, R. M., and Steinberg, G. K. (1998) Gene therapy with HSP72 is neuroprotective in rat models of stroke and epilepsy. Ann. Neurol.44, 584–591.
Yamada, M., Oligino, T., Mata, M., Goss, J. R., Glorioso, J. C., and Fink, D. J. (1999) Herpes simplex virus vector-mediated expression of Bcl-2 prevents 6-hydroxydopamine-induced degeneration of neurons in the substantia nigra in vivo. Proc. Natl. Acad. Sci. USA 96, 4078–4083.
Martino, G., Poliani, P. L., Furlan, R., Marconi, P., Glorioso, J. C., Adorini, L., and Comi, G. (2000) Cytokine therapy in immune-mediated demyelinating diseases of the central nervous system: a novel gene therapy approach. J. Neuroimmunol. 107, 184–190.
Sun, M., Kong, L., Wang, X., Holmes, C., Gao, Q., Zhang, G. R., Pfeilschifter, J., Goldstein, D. S., and Geller, A. I. (2004) Coexpression of tyrosine hydroxylase, GTP cyclohydrolase I, aromatic amino acid decarboxylase, and vesicular monoamine transporter 2 from a helper virus-free herpes simplex virus type 1 vector supports high-level, long-term biochemical and behavioral correction of a rat model of Parkinson's disease. Hum. Gene Ther. 15, 1177–1196.
Samaniego, L. A., Neiderhiser, L., and DeLuca, N. A. (1998) Persistence and expression of the herpes simplex virus genome in the absence of immediate-early proteins. J. Virol. 72, 3307–3320.
Bell, J. C., Lichty, B., and Stojdl, D. (2003) Getting oncolytic virus therapies off the ground. Cancer Cell 4, 7–11.
Kesari, S., Randazzo, B. P., Valyi-Nagy, T., Huang, Q. S., Brown, S. M., MacLean, A. R., Lee, V. M., Trojanowski, J. Q., and Fraser, N. W. (1995) Therapy of experimental human brain tumors using a neuroattenuated herpes simplex virus mutant. Lab. Invest. 73, 636–648.
Yoon, S. S., Nakamura, H., Carroll, N. M., Bode, B. P., Chiocca, E. A., and Tanabe, K. K. (2000) An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma. FASEB J. 14, 301–311.
Varghese, S., and Rabkin, S. D. (2002) Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther. 9, 967–978.
Markert, J. M., Medlock, M. D., Rabkin, S. D., Gillespie, G. Y., Todo, T., Hunter, W. D., Palmer, C. A., Feigenbaum, F., Tornatore, C., Tufaro, F., and Martuza, R. L. (2000) Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther. 7, 867–874.
Rampling, R., Cruickshank, G., Papanastassiou, V., Nicoll, J., Hadley, D., Brennan, D., Petty, R., MacLean, A., Harland, J., McKie, E., Mabbs, R., and Brown, M. (2000) Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther. 7, 859–866.
Papanastassiou, V., Rampling, R., Fraser, M., Petty, R., Hadley, D., Nicoll, J., Harland, J., Mabbs, R., and Brown, M. (2002) The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study. Gene Ther. 9, 398–406.
MacKie, R. M., Stewart, B., and Brown, S. M. (2001) Intralesional injection of herpes simplex virus 1716 in metastatic melanoma. Lancet 357, 525–526.
Liddington, R. C., Yan, Y., Moulai, J., Sahli, R., Benjamin, T. L., and Harrison, S. C. (1991) Structure of simian virus 40 at 3.8-A resolution. Nature 354, 278–284.
Nakanishi, A., Nakamura, A., Liddington, R., and Kasamatsu, H. (2006) Identification of amino acid residues within simian virus 40 capsid proteins Vp1, Vp2, and Vp3 that are required for their interaction and for viral infection. J. Virol. 80, 8891–8898.
Kimchi-Sarfaty, C., and Gottesman, M. M. (2006) SV40 In vitro packaging: a psuedovirion gene delivery system. In: Friedman, T. and Rossi, J., eds. Gene Transfer. Woodbury, NY: Cold Spring Harbor Laboratory Press, 289–296.
Marple, A. H., Gottesman, M. M., and Kimchi-Sarfaty, C. (2007) Efficient gene therapy delivery by SV40-derived vectors. In: Hefferon, K., ed. Virus Expression Vectors. Woodbury, Trivandrum, India: Transworld Research Network.
Strayer, D. S. (1999) Gene therapy using SV40-derived vectors: what does the future hold? J. Cell Physiol. 181, 375–384.
Kimchi-Sarfaty, C., Garfield, S., Nathan, A. S., Saadia, A., Carlos, C., Dhanalakshmi, C., and Gottesman, M. M. (2004) The pathway of uptake of SV40 pseudovirions packaged in vitro: from MHC class I receptors to the nucleus. Ther. Mol. Biol. 8, 439–450.
Rund, D., Dagan, M., Dalyot-Herman, N., Kimchi-Sarfaty, C., Schoenlein, P. V., Gottesman, M. M., and Oppenheim, A. (1998) Efficient transduction of human hematopoietic cells with the human multidrug resistance gene 1 via SV40 pseudovirions. Hum. Gene Ther. 9, 649–657.
Kimchi-Sarfaty, C., Vieira, W. D., Dodds, D., Sherman, A., Kreitman, R. J., Shinar, S., and Gottesman, M. M. (2006) SV40 Pseudovirion gene delivery of a toxin to treat human adenocarcinomas in mice. Cancer Gene Ther. 13, 648–657.
Kodama, K., Katayama, Y., Shoji, Y., and Nakashima, H. (2006) The features and shortcomings for gene delivery of current non-viral carriers. Curr. Med. Chem. 13, 2155–2161.
Park, T. G., Jeong, J. H., and Kim, S. W. (2006) Current status of polymeric gene delivery systems. Adv. Drug Deliv. Rev. 58, 467–486.
Gardlik, R., Palffy, R., Hodosy, J., Lukacs, J., Turna, J., and Celec, P. (2005) Vectors and delivery systems in gene therapy. Med. Sci. Monit. 11, RA110–121.
Smith, B. F., Baker, H. J., Curiel, D. T., Jiang, W., and Conry, R. M. (1998) Humoral and cellular immune responses of dogs immunized with a nucleic acid vaccine encoding human carcinoembryonic antigen. Gene Ther. 5, 865–868.
Velaz-Faircloth, M., Cobb, A. J., Horstman, A. L., Henry, S. C., and Frothingham, R. (1999) Protection against Mycobacterium avium by DNA vaccines expressing mycobacterial antigens as fusion proteins with green fluorescent protein. Infect. Immun. 67, 4243–4250.
Yu, W. H., Kashani-Sabet, M., Liggitt, D., Moore, D., Heath, T. D., and Debs, R. J. (1999) Topical gene delivery to murine skin. J. Invest. Dermatol. 112, 370–375.
Zhang, G., Vargo, D., Budker, V., Armstrong, N., Knechtle, S., and Wolff, J. A. (1997) Expression of naked plasmid DNA injected into the afferent and efferent vessels of rodent and dog livers. Hum. Gene Ther. 8, 1763–1772.
Yang, J. P., and Huang, L. (1996) Direct gene transfer to mouse melanoma by intratumor injection of free DNA. Gene Ther. 3, 542–548.
Tupin, E., Poirier, B., Bureau, M. F., Khallou-Laschet, J., Vranckx, R., Caligiuri, G., Gaston, A. T., Duong Van Huyen, J. P., Scherman, D., Bariety, J., Michel, J. B., and Nicoletti, A. (2003) Non-viral gene transfer of murine spleen cells achieved by in vivo electroporation. Gene Ther. 10, 569–579.
Gronevik, E., Mathiesen, I., and Lomo, T. (2005) Early events of electroporation-mediated intramuscular DNA vaccination potentiate Th1-directed immune responses. J. Gene Med. 7, 1246–1254.
Dileo, J., Miller, T. E., Jr., Chesnoy, S., and Huang, L. (2003) Gene transfer to subdermal tissues via a new gene gun design. Hum. Gene Ther. 14, 79–87.
Matsuno, Y., Iwata, H., Umeda, Y., Takagi, H., Mori, Y., Miyazaki, J., Kosugi, A., and Hirose, H. (2003) Nonviral gene gun mediated transfer into the beating heart. ASAIO J. 49, 641–644.
Yoshizawa, J., Li, X. K., Fujino, M., Kimura, H., Mizuno, R., Hara, A., Ashizuka, S., Kanai, M., Kuwashima, N., Kurobe, M., and Yamazaki, Y. (2004) Successful in utero gene transfer using a gene gun in midgestational mouse fetuses. J. Pediatr. Surg. 39, 81–84.
Kodama, T., Tan, P. H., Offiah, I., Partridge, T., Cook, T., George, A. J., and Blomley, M. J. (2005) Delivery of oligodeoxynucleotides into human saphenous veins and the adjunct effect of ultrasound and microbubbles. Ultrasound Med. Biol. 31, 1683–1691.
Haag, P., Frauscher, F., Gradl, J., Seitz, A., Schafer, G., Lindner, J. R., Klibanov, A. L., Bartsch, G., Klocker, H., and Eder, I. E. (2006) Microbubble-enhanced ultrasound to deliver an antisense oligodeoxynucleotide targeting the human androgen receptor into prostate tumours. J. Steroid Biochem. Mol. Biol. 102, 103–113.
Felgner, P. L., Gadek, T. R., Holm, M., Roman, R., Chan, H. W., Wenz, M., Northrop, J. P., Ringold, G. M., and Danielsen, M. (1987) Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc. Natl. Acad. Sci. USA 84, 7413–7417.
Dass, C. R. (2002) Biochemical and biophysical characteristics of lipoplexes pertinent to solid tumour gene therapy. Int. J. Pharm. 241, 1–25.
Zhdanov, R. I., Podobed, O. V., and Vlassov, V. V. (2002) Cationic lipid-DNA complexes-lipoplexes-for gene transfer and therapy. Bioelectrochemistry 58, 53–64.
Farhood, H., Serbina, N., and Huang, L. (1995) The role of dioleoyl phosphatidylethanolamine in cationic liposome mediated gene transfer. Biochim. Biophys. Acta 1235, 289–295.
Hong, K., Zheng, W., Baker, A., and Papahadjopoulos, D. (1997) Stabilization of cationic liposome-plasmid DNA complexes by polyamines and poly(ethylene glycol)-phospholipid conjugates for efficient in vivo gene delivery. FEBS Lett. 400, 233–237.
Semple, S. C., Chonn, A., and Cullis, P. R. (1996) Influence of cholesterol on the association of plasma proteins with liposomes. Biochemistry 35, 2521–2525.
Hattori, Y., Kawakami, S., Nakamura, K., Yamashita, F., and Hashida, M. (2006) Efficient gene transfer into macrophages and dendritic cells by in vivo gene delivery with mannosylated lipoplex via the intraperitoneal route. J. Pharmacol. Exp. Ther. 318, 828–834.
Hattori, Y., Suzuki, S., Kawakami, S., Yamashita, F., and Hashida, M. (2005) The role of dioleoylphosphatidylethanolamine (DOPE) in targeted gene delivery with mannosylated cationic liposomes via intravenous route. J. Control. Release 108, 484–495.
Kawakami, S., Harada, A., Sakanaka, K., Nishida, K., Nakamura, J., Sakaeda, T., Ichikawa, N., Nakashima, M., and Sasaki, H. (2004) In vivo gene transfection via intravitreal injection of cationic liposome/plasmid DNA complexes in rabbits. Int. J. Pharm. 278, 255–262.
Monck, M. A., Mori, A., Lee, D., Tam, P., Wheeler, J. J., Cullis, P. R., and Scherrer, P. (2000) Stabilized plasmid-lipid particles: pharmacokinetics and plasmid delivery to distal tumors following intravenous injection. J. Drug. Target. 7, 439–452.
Ishiwata, H., Suzuki, N., Ando, S., Kikuchi, H., and Kitagawa, T. (2000) Characteristics and biodistribution of cationic liposomes and their DNA complexes. J. Control. Rel. 69, 139–148.
Anwer, K., Kao, G., Proctor, B., Anscombe, I., Florack, V., Earls, R., Wilson, E., McCreery, T., Unger, E., Rolland, A., and Sullivan, S. M. (2000) Ultrasound enhancement of cationic lipid-mediated gene transfer to primary tumors following systemic administration. Gene Ther. 7, 1833–1839.
Anwer, K., Kao, G., Proctor, B., Rolland, A., and Sullivan, S. (2000) Optimization of cationic lipid/DNA complexes for systemic gene transfer to tumor lesions. J. Drug Target. 8, 125–135.
Wu, C. H., Wilson, J. M., and Wu, G. Y. (1989) Targeting genes: delivery and persistent expression of a foreign gene driven by mammalian regulatory elements in vivo. J. Biol. Chem. 264, 16985–16987.
Wagner, E., Ogris, M., and Zauner, W. (1998) Polylysine-based transfection systems utilizing receptor-mediated delivery. Adv. Drug. Deliv. Rev. 30, 97–113.
Schaffer, D. V., and Lauffenburger, D. A. (1998) Optimization of cell surface binding enhances efficiency and specificity of molecular conjugate gene delivery. J. Biol. Chem. 273, 28004–28009.
Forrest, M. L., and Pack, D. W. (2002) On the kinetics of polyplex endocytic trafficking: implications for gene delivery vector design. Mol. Ther. 6, 57–66.
Pouton, C. W., Lucas, P., Thomas, B. J., Uduehi, A. N., Milroy, D. A., and Moss, S. H. (1998) Polycation-DNA complexes for gene delivery: a comparison of the biopharmaceutical properties of cationic polypeptides and cationic lipids. J. Control Rel. 53, 289–299.
Kircheis, R., Kichler, A., Wallner, G., Kursa, M., Ogris, M., Felzmann, T., Buchberger, M., and Wagner, E. (1997) Coupling of cell-binding ligands to polyethylenimine for targeted gene delivery. Gene Ther. 4, 409–418.
Dash, P. R., Read, M. L., Barrett, L. B., Wolfert, M. A., and Seymour, L. W. (1999) Factors affecting blood clearance and in vivo distribution of polyelectrolyte complexes for gene delivery. Gene Ther. 6, 643–650.
Nguyen, H. K., Lemieux, P., Vinogradov, S. V., Gebhart, C. L., Guerin, N., Paradis, G., Bronich, T. K., Alakhov, V. Y., and Kabanov, A. V. (2000) Evaluation of polyether-polyethyleneimine graft copolymers as gene transfer agents. Gene Ther. 7, 126–138.
Hudde, T., Rayner, S. A., Comer, R. M., Weber, M., Isaacs, J. D., Waldmann, H., Larkin, D. F., and George, A. J. (1999) Activated polyamidoamine dendrimers, a non-viral vector for gene transfer to the corneal endothelium. Gene Ther. 6, 939–943.
Dennig, J., and Duncan, E. (2002) Gene transfer into eukaryotic cells using activated polyamidoamine dendrimers. J. Biotechnol. 90, 339–347.
Truong-Le, V. L., August, J. T., and Leong, K. W. (1998) Controlled gene delivery by DNA-gelatin nanospheres. Hum. Gene Ther. 9, 1709–1717.
van de Wetering, P., Moret, E. E., Schuurmans-Nieuwenbroek, N. M., van Steenbergen, M. J., and Hennink, W. E. (1999) Structure-activity relationships of water-soluble cationic methacrylate/methacrylamide polymers for nonviral gene delivery. Bioconjug. Chem. 10, 589–597.
van der Woude, I., Wagenaar, A., Meekel, A. A., ter Beest, M. B., Ruiters, M. H., Engberts, J. B., and Hoekstra, D. (1997) Novel pyridinium surfactants for efficient, nontoxic in vitro gene delivery. Proc. Natl. Acad. Sci. USA 94, 1160–1165.
Mansouri, S., Lavigne, P., Corsi, K., Benderdour, M., Beaumont, E., and Fernandes, J. C. (2004) Chitosan-DNA nanoparticles as non-viral vectors in gene therapy: strategies to improve transfection efficacy. Eur. J. Pharm. Biopharm. 57, 1–8.
Chen, J., Yang, W. L., Li, G., Qian, J., Xue, J. L., Fu, S. K., and Lu, D. R. (2004) Transfection of mEpo gene to intestinal epithelium in vivo mediated by oral delivery of chitosan-DNA nanoparticles. World J. Gastroenterol. 10, 112–116.
Roy, K., Mao, H. Q., Huang, S. K., and Leong, K. W. (1999) Oral gene delivery with chitosan – DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat. Med. 5, 387–391.
Gomez-Sebastian, S., Gimenez-Cassina, A., Diaz-Nido, J., Lim, F., and Wade-Martins, R. (2007) Infectious delivery and expression of a 135 kb human FRDA genomic DNA locus complements Friedreich's ataxia deficiency in human cells. Mol. Ther. 15, 248–254.
Hibbitt, O. C., Harbottle, R. P., Waddington, S. N., Bursill, C. A., Coutelle, C., Channon, K. M., and Wade-Martins, R. (2007) Delivery and long-term expression of a 135 kb LDLR genomic DNA locus in vivo by hydrodynamic tail vein injection. J. Gene Med. 9, 488–497.
Kanzaki, S., Beyer, L., Karolyi, I. J., Dolan, D. F., Fang, Q., Probst, F. J., Camper, S. A., and Raphael, Y. (2006) Transgene correction maintains normal cochlear structure and function in 6-month-old Myo15a mutant mice. Hear. Res. 214, 37–44.
Lim, F., Palomo, G. M., Mauritz, C., Gimenez-Cassina, A., Illana, B., Wandosell, F., and Diaz-Nido, J. (2007) Functional recovery in a Friedreich's ataxia mouse model by frataxin gene transfer using an HSV-1 amplicon vector. Mol. Ther. 15, 1072–1078.
Suda, T., Katoh, M., Hiratsuka, M., Takiguchi, M., Kazuki, Y., Inoue, T., and Oshimura, M. (2006) Heat-regulated production and secretion of insulin from a human artificial chromosome vector. Biochem. Biophys. Res. Commun. 340, 1053–1061.
Paglia, P., Medina, E., Arioli, I., Guzman, C. A., and Colombo, M. P. (1998) Gene transfer in dendritic cells, induced by oral DNA vaccination with Salmonella typhimurium, results in protective immunity against a murine fibrosarcoma. Blood 92, 3172–3176.
Sizemore, D. R., Branstrom, A. A., and Sadoff, J. C. (1995) Attenuated Shigella as a DNA delivery vehicle for DNA-mediated immunization. Science 270, 299–302.
Vassaux, G., Nitcheu, J., Jezzard, S., and Lemoine, N. R. (2006) Bacterial gene therapy strategies. J. Pathol. 208, 290–298.
Palffy, R., Gardlik, R., Hodosy, J., Behuliak, M., Resko, P., Radvansky, J., and Celec, P. (2006) Bacteria in gene therapy: bactofection versus alternative gene therapy. Gene Ther. 13, 101–105.
Al-Mariri, A., Tibor, A., Lestrate, P., Mertens, P., De Bolle, X., and Letesson, J. J. (2002) Yersinia enterocolitica as a vehicle for a naked DNA vaccine encoding Brucella abortus bacterioferritin or P39 antigen. Infect. Immun. 70, 1915–1923.
Woo, P. C., Wong, L. P., Zheng, B. J., and Yuen, K. Y. (2001) Unique immunogenicity of hepatitis B virus DNA vaccine presented by live-attenuated Salmonella typhimurium. Vaccine 19, 2945–2954.
Flo, J., Tisminetzky, S., and Baralle, F. (2001) Oral transgene vaccination mediated by attenuated Salmonellae is an effective method to prevent Herpes simplex virus-2 induced disease in mice. Vaccine 19, 1772–1782.
Niethammer, A. G., Xiang, R., Becker, J. C., Wodrich, H., Pertl, U., Karsten, G., Eliceiri, B. P., and Reisfeld, R. A. (2002) A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat. Med. 8, 1369–1375.
Feng, K. K., Zhao, H. Y., Qiu, H., Liu, J. X., and Chen, J. (2005) Combined therapy with flk1-based DNA vaccine and interleukin-12 results in enhanced antiangiogenic and antitumor effects. Cancer Lett. 221, 41–47.
Theys, J., Landuyt, A. W., Nuyts, S., Van Mellaert, L., Lambin, P., and Anne, J. (2001) Clostridium as a tumor-specific delivery system of therapeutic proteins. Cancer Detect. Prev. 25, 548–557.
Fujimori, M., Amano, J., and Taniguchi, S. (2002) The genus Bifidobacterium for cancer gene therapy. Curr. Opin. Drug Discov. Dev. 5, 200–203.
Luo, X., Li, Z., Lin, S., Le, T., Ittensohn, M., Bermudes, D., Runyab, J. D., Shen, S. Y., Chen, J., King, I. C., and Zheng, L. M. (2001) Antitumor effect of VNP20009, an attenuated Salmonella, in murine tumor models. Oncol. Res. 12, 501–508.
Nemunaitis, J., Cunningham, C., Senzer, N., Kuhn, J., Cramm, J., Litz, C., Cavagnolo, R., Cahill, A., Clairmont, C., and Sznol, M. (2003) Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients. Cancer Gene Ther. 10, 737–744.
Nuyts, S., Van Mellaert, L., Theys, J., Landuyt, W., Lambin, P., and Anne, J. (2001) The use of radiation-induced bacterial promoters in anaerobic conditions: a means to control gene expression in clostridium-mediated therapy for cancer. Radiat. Res. 155, 716–723.
Kumar, S., Walia, V., Ray, M., and Elble, R. C. (2007) p53 in breast cancer: mutation and countermeasures. Front Biosci. 12, 4168–4178.
Cai, D. W., Mukhopadhyay, T., Liu, Y., Fujiwara, T., and Roth, J. A. (1993) Stable expression of the wild-type p53 gene in human lung cancer cells after retrovirus-mediated gene transfer. Hum. Gene Ther. 4, 617–624.
Watts, G. S., Oshiro, M. M., Junk, D. J., Wozniak, R. J., Watterson, S., Domann, F. E., and Futscher, B. W. (2004) The acetyltransferase p300/CBP-associated factor is a p53 target gene in breast tumor cells. Neoplasia 6, 187–194.
Eastham, J. A., Grafton, W., Martin, C. M., and Williams, B. J. (2000) Suppression of primary tumor growth and the progression to metastasis with p53 adenovirus in human prostate cancer. J. Urol. 164, 814–819.
Giuliano, M., Catalano, A., Strizzi, L., Vianale, G., Capogrossi, M., and Procopio, A. (2000) Adenovirus-mediated wild-type p53 overexpression reverts tumourigenicity of human mesothelioma cells. Int. J. Mol. Med. 5, 591–596.
Su, S., Watanabe, A., Yamamoto, M., Nakajima, E., Miyake, K., and Shimada, T. (2006) Mutations in p53 cDNA sequence introduced by retroviral vector. Biochem. Biophys. Res. Commun. 340, 567–572.
Guo, J., and Xin, H. (2006) Chinese gene therapy. Splicing out the West? Science 314, 1232–1235.
Gabrilovich, D. I. (2006) INGN 201 (Advexin): adenoviral p53 gene therapy for cancer. Expert Opin. Biol. Ther. 6, 823–832.
Pisters, L. L., Pettaway, C. A., Troncoso, P., McDonnell, T. J., Stephens, L. C., Wood, C. G., Do, K. A., Brisbay, S. M., Wang, X., Hossan, E. A., Evans, R. B., Soto, C., Jacobson, M. G., Parker, K., Merritt, J. A., Steiner, M. S., and Logothetis, C. J. (2004) Evidence that transfer of functional p53 protein results in increased apoptosis in prostate cancer. Clin. Cancer Res. 10, 2587–2593.
Swisher, S. G., Roth, J. A., Komaki, R., Gu, J., Lee, J. J., Hicks, M., Ro, J. Y., Hong, W. K., Merritt, J. A., Ahrar, K., Atkinson, N. E., Correa, A. M., Dolormente, M., Dreiling, L., El-Naggar, A. K., Fossella, F., Francisco, R., Glisson, B., Grammer, S., Herbst, R., Huaringa, A., Kemp, B., Khuri, F. R., Kurie, J. M., Liao, Z., McDonnell, T. J., Morice, R., Morello, F., Munden, R., Papadimitrakopoulou, V., Pisters, K. M., Putnam, J. B., Jr., Sarabia, A. J., Shelton, T., Stevens, C., Shin, D. M., Smythe, W. R., Vaporciyan, A. A., Walsh, G. L., and Yin, M. (2003) Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin. Cancer Res. 9, 93–101.
Lockley, M., Fernandez, M., Wang, Y., Li, N. F., Conroy, S., Lemoine, N., and McNeish, I. (2006) Activity of the adenoviral E1A deletion mutant dl922–947 in ovarian cancer: comparison with E1A wild-type viruses, bioluminescence monitoring, and intraperitoneal delivery in icodextrin. Cancer Res. 66, 989–998.
Zabarovsky, E. R., Lerman, M. I., and Minna, J. D. (2002) Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers. Oncogene 21, 6915–6935.
Ji, L., Nishizaki, M., Gao, B., Burbee, D., Kondo, M., Kamibayashi, C., Xu, K., Yen, N., Atkinson, E. N., Fang, B., Lerman, M. I., Roth, J. A., and Minna, J. D. (2002) Expression of several genes in the human chromosome 3p21.3 homozygous deletion region by an adenovirus vector results in tumor suppressor activities in vitro and in vivo. Cancer Res. 62, 2715–2720.
Deng, W. G., Nishizaki, M., Fang, B., Roth, J. A., and Ji, L. (2007) Induction of apoptosis by tumor suppressor FHIT via death receptor signaling pathway in human lung cancer cells. Biochem. Biophys. Res. Commun. 355, 993–999.
Guo, W., Zhu, H., Zhang, L., Davis, J., Teraishi, F., Roth, J. A., Stephens, C., Fueyo, J., Jiang, H., Conrad, C., and Fang, B. (2006) Combination effect of oncolytic adenovirotherapy and TRAIL gene therapy in syngeneic murine breast cancer models. Cancer Gene Ther. 13, 82–90.
Fillat, C., Carrio, M., Cascante, A., and Sangro, B. (2003) Suicide gene therapy mediated by the Herpes Simplex virus thymidine kinase gene/Ganciclovir system: fifteen years of application. Curr. Gene Ther. 3, 13–26.
Negroni, L., Samson, M., Guigonis, J. M., Rossi, B., Pierrefite-Carle, V., and Baudoin, C. (2007) Treatment of colon cancer cells using the cytosine deaminase/5-fluorocytosine suicide system induces apoptosis, modulation of the proteome, and Hsp90beta phosphorylation. Mol. Cancer Ther. 6, 2747–2756.
Braybrooke, J. P., Slade, A., Deplanque, G., Harrop, R., Madhusudan, S., Forster, M. D., Gibson, R., Makris, A., Talbot, D. C., Steiner, J., White, L., Kan, O., Naylor, S., Carroll, M. W., Kingsman, S. M., and Harris, A. L. (2005) Phase I study of MetXia-P450 gene therapy and oral cyclophosphamide for patients with advanced breast cancer or melanoma. Clin. Cancer Res. 11, 1512–1520.
Dachs, G. U., Tupper, J., and Tozer, G. M. (2005) From bench to bedside for gene-directed enzyme prodrug therapy of cancer. Anticancer Drugs 16, 349–359.
Mathis, J. M., Williams, B. J., Sibley, D. A., Carroll, J. L., Li, J., Odaka, Y., Barlow, S., Nathan, C. O., Li, B. D., and DeBenedetti, A. (2006) Cancer-specific targeting of an adenovirus-delivered herpes simplex virus thymidine kinase suicide gene using translational control. J. Gene Med. 8, 1105–1120.
Kagaya, T., Nakamoto, Y., Sakai, Y., Tsuchiyama, T., Yagita, H., Mukaida, N., and Kaneko, S. (2006) Monocyte chemoattractant protein-1 gene delivery enhances antitumor effects of herpes simplex virus thymidine kinase/ganciclovir system in a model of colon cancer. Cancer Gene Ther. 13, 357–366.
Zhan, J., Gao, Y., Wang, W., Shen, A., Aspelund, A., Young, M., Laquerre, S., Post, L., and Shen, Y. (2005) Tumor-specific intravenous gene delivery using oncolytic adenoviruses. Cancer Gene Ther. 12, 19–25.
Liu, Y., and Deisseroth, A. (2006) Oncolytic adenoviral vector carrying the cytosine deaminase gene for melanoma gene therapy. Cancer Gene Ther. 13, 845–855.
Wang, J., Lu, X. X., Chen, D. Z., Li, S. F., and Zhang, L. S. (2004) Herpes simplex virus thymidine kinase and ganciclovir suicide gene therapy for human pancreatic cancer. World J. Gastroenterol. 10, 400–403.
Fogar, P., Greco, E., Basso, D., Habeler, W., Navaglia, F., Zambon, C. F., Tormen, D., Gallo, N., Cecchetto, A., Plebani, M., and Pedrazzoli, S. (2003) Suicide gene therapy with HSV-TK in pancreatic cancer has no effect in vivo in a mouse model. Eur. J. Surg. Oncol. 29, 721–730.
Shand, N., Weber, F., Mariani, L., Bernstein, M., Gianella-Borradori, A., Long, Z., Sorensen, A. G., and Barbier, N. (1999) A phase 1–2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group. Hum. Gene Ther. 10, 2325–2335.
Rainov, N. G. (2000) A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum. Gene Ther. 11, 2389–2401.
Kikuchi, E., Menendez, S., Ozu, C., Ohori, M., Cordon-Cardo, C., Logg, C. R., Kasahara, N., and Bochner, B. H. (2007) Delivery of replication-competent retrovirus expressing Escherichia coli purine nucleoside phosphorylase increases the metabolism of the prodrug, fludarabine phosphate and suppresses the growth of bladder tumor xenografts. Cancer Gene Ther. 14, 279–286.
Stover, M. L., Wang, C. K., McKinstry, M. B., Kalajzic, I., Gronowicz, G., Clark, S. H., Rowe, D. W., and Lichtler, A. C. (2001) Bone-directed expression of Col1a1 promoter-driven self-inactivating retroviral vector in bone marrow cells and transgenic mice. Mol. Ther. 3, 543–550.
Vile, R. G., Diaz, R. M., Miller, N., Mitchell, S., Tuszyanski, A., and Russell, S. J. (1995) Tissue-specific gene expression from Mo-MLV retroviral vectors with hybrid LTRs containing the murine tyrosinase enhancer/promoter. Virology 214, 307–313.
Engels, B., Cam, H., Schuler, T., Indraccolo, S., Gladow, M., Baum, C., Blankenstein, T., and Uckert, W. (2003) Retroviral vectors for high-level transgene expression in T lymphocytes. Hum. Gene Ther. 14, 1155–1168.
Wang, J. M., Hou, J., Qiu, X. F., Kurachi, K., and Xue, J. L. (2004) Hybrid retroviral vector with MCK enhancers inserted in LTR for stable and specific expression of human factor IX in skeletal muscle. Chin. Med. J. (Engl) 117, 893–898.
Woo, Y., Adusumilli, P. S., and Fong, Y. (2006) Advances in oncolytic viral therapy. Curr. Opin. Investig. Drugs 7, 549–559.
Crompton, A. M., and Kirn, D. H. (2007) From ONYX-015 to armed vaccinia viruses: the education and evolution of oncolytic virus development. Curr. Cancer Drug Targets 7, 133–139.
Barzon, L., Zanusso, M., Colombo, F., and Palu, G. (2006) Clinical trials of gene therapy, virotherapy, and immunotherapy for malignant gliomas. Cancer Gene Ther. 13, 539–554.
Hotte, S. J., Lorence, R. M., Hirte, H. W., Polawski, S. R., Bamat, M. K., O'Neil, J. D., Roberts, M. S., Groene, W. S., and Major, P. P. (2007) An optimized clinical regimen for the oncolytic virus PV701. Clin. Cancer Res. 13, 977–985.
Laurie, S. A., Bell, J. C., Atkins, H. L., Roach, J., Bamat, M. K., O'Neil, J. D., Roberts, M. S., Groene, W. S., and Lorence, R. M. (2006) A phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization. Clin. Cancer Res. 12, 2555–2562.
Lorence, R. M., Roberts, M. S., O'Neil, J. D., Groene, W. S., Miller, J. A., Mueller, S. N., and Bamat, M. K. (2007) Phase 1 clinical experience using intravenous administration of PV701, an oncolytic Newcastle disease virus. Curr. Cancer Drug Targets 7, 157–167.
Pecora, A. L., Rizvi, N., Cohen, G. I., Meropol, N. J., Sterman, D., Marshall, J. L., Goldberg, S., Gross, P., O'Neil, J. D., Groene, W. S., Roberts, M. S., Rabin, H., Bamat, M. K., and Lorence, R. M. (2002) Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J. Clin. Oncol. 20, 2251–2266.
Marcato, P., Shmulevitz, M., Pan, D., Stoltz, D., and Lee, P. W. (2007) Ras transformation mediates reovirus oncolysis by enhancing virus uncoating, particle infectivity, and apoptosis-dependent release. Mol. Ther. 15, 1522–1530.
Hallahan, D. E., Beckett, M. A., Kufe, D., and Weichselbaum, R. R. (1990) The interaction between recombinant human tumor necrosis factor and radiation in 13 human tumor cell lines. Int. J. Radiat. Oncol. Biol. Phys. 19, 69–74.
Hallahan, D. E., Spriggs, D. R., Beckett, M. A., Kufe, D. W., and Weichselbaum, R. R. (1989) Increased tumor necrosis factor alpha mRNA after cellular exposure to ionizing radiation. Proc. Natl. Acad. Sci. USA 86, 10104–10107.
Datta, R., Rubin, E., Sukhatme, V., Qureshi, S., Hallahan, D., Weichselbaum, R. R., and Kufe, D. W. (1992) Ionizing radiation activates transcription of the EGR1 gene via CArG elements. Proc. Natl. Acad. Sci. USA 89, 10149–10153.
Mezhir, J. J., Smith, K. D., Posner, M. C., Senzer, N., Yamini, B., Kufe, D. W., and Weichselbaum, R. R. (2006) Ionizing radiation: a genetic switch for cancer therapy. Cancer Gene Ther. 13, 1–6.
Weichselbaum, R. R., Hallahan, D. E., Beckett, M. A., Mauceri, H. J., Lee, H., Sukhatme, V. P., and Kufe, D. W. (1994) Gene therapy targeted by radiation preferentially radiosensitizes tumor cells. Cancer Res. 54, 4266–4269.
Seung, L. P., Mauceri, H. J., Beckett, M. A., Hallahan, D. E., Hellman, S., and Weichselbaum, R. R. (1995) Genetic radiotherapy overcomes tumor resistance to cytotoxic agents. Cancer Res. 55, 5561–5565.
Chung, T. D., Mauceri, H. J., Hallahan, D. E., Yu, J. J., Chung, S., Grdina, W. L., Yajnik, S., Kufe, D. W., and Weichselbaum, R. R. (1998) Tumor necrosis factor-alpha-based gene therapy enhances radiation cytotoxicity in human prostate cancer. Cancer Gene Ther. 5, 344–349.
Staba, M. J., Mauceri, H. J., Kufe, D. W., Hallahan, D. E., and Weichselbaum, R. R. (1998) Adenoviral TNF-alpha gene therapy and radiation damage tumor vasculature in a human malignant glioma xenograft. Gene Ther. 5, 293–300.
Senzer, N., Mani, S., Rosemurgy, A., Nemunaitis, J., Cunningham, C., Guha, C., Bayol, N., Gillen, M., Chu, K., Rasmussen, C., Rasmussen, H., Kufe, D., Weichselbaum, R., and Hanna, N. (2004) TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors. J. Clin. Oncol. 22, 592–601.
Mundt, A. J., Vijayakumar, S., Nemunaitis, J., Sandler, A., Schwartz, H., Hanna, N., Peabody, T., Senzer, N., Chu, K., Rasmussen, C. S., Kessler, P. D., Rasmussen, H. S., Warso, M., Kufe, D. W., Gupta, T. D., and Weichselbaum, R. R. (2004) A Phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremities. Clin. Cancer Res. 10, 5747–5753.
Mezhir, J. J., Schmidt, H., Yamini, B., Senzer, N. N., Posner, M. C., Kufe, D. W., and Weichselbaum, R. R. (2005) Chemo-inducible gene therapy. Anticancer Drugs 16, 1053–1058.
Lopez, C. A., Kimchi, E. T., Mauceri, H. J., Park, J. O., Mehta, N., Murphy, K. T., Beckett, M. A., Hellman, S., Posner, M. C., Kufe, D. W., and Weichselbaum, R. R. (2004) Chemoinducible gene therapy: a strategy to enhance doxorubicin antitumor activity. Mol. Cancer Ther. 3, 1167–1175.
Park, J. O., Lopez, C. A., Gupta, V. K., Brown, C. K., Mauceri, H. J., Darga, T. E., Manan, A., Hellman, S., Posner, M. C., Kufe, D. W., and Weichselbaum, R. R. (2002) Transcriptional control of viral gene therapy by cisplatin. J. Clin. Invest. 110, 403–410.
Yamini, B., Yu, X., Gillespie, G. Y., Kufe, D. W., and Weichselbaum, R. R. (2004) Transcriptional targeting of adenovirally delivered tumor necrosis factor alpha by temozolomide in experimental glioblastoma. Cancer Res. 64, 6381–6384.
Yamini, B., Yu, X., Pytel, P., Galanopoulos, N., Rawlani, V., Veerapong, J., Bickenbach, K., and Weichselbaum, R. R. (2007) Adenovirally Delivered Tumor Necrosis Factor-{alpha} Improves the Antiglioma Efficacy of Concomitant Radiation and Temozolomide Therapy. Clin. Cancer Res. 13, 6217–6223.
Walther, W., Stein, U., Fichtner, I., Alexander, M., Shoemaker, R. H., and Schlag, P. M. (2000) Mdr1 promoter-driven tumor necrosis factor-alpha expression for a chemotherapy-controllable combined in vivo gene therapy and chemotherapy of tumors. Cancer Gene Ther. 7, 893–900.
Walther, W., Stein, U., and Schlag, P. M. (2002) Use of the human MDR1 promoter for heat-inducible expression of therapeutic genes. Int. J. Cancer 98, 291–296.
Walther, W., Arlt, F., Fichtner, I., Aumann, J., Stein, U., and Schlag, P. M. (2007) Heat-inducible in vivo gene therapy of colon carcinoma by human mdr1 promoter-regulated tumor necrosis factor-alpha expression. Mol. Cancer Ther. 6, 236–243.
Devi, G. R. (2006) siRNA-based approaches in cancer therapy. Cancer Gene Ther. 13, 819–829.
Karagiannis, T. C., and El-Osta, A. (2005) RNA interference and potential therapeutic applications of short interfering RNAs. Cancer Gene Ther. 12, 787–795.
O'Reilly, M. S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R. A., Moses, M., Lane, W. S., Cao, Y., Sage, E. H., and Folkman, J. (1994) Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79, 315–328.
O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., and Folkman, J. (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88, 277–285.
Dawson, D. W., Volpert, O. V., Gillis, P., Crawford, S. E., Xu, H., Benedict, W., and Bouck, N. P. (1999) Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 285, 245–248.
Millauer, B., Longhi, M. P., Plate, K. H., Shawver, L. K., Risau, W., Ullrich, A., and Strawn, L. M. (1996) Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res. 56, 1615–1620.
Mae, M., O'Connor, T. P., and Crystal, R. G. (2005) Gene transfer of the vascular endothelial growth factor receptor flt-1 suppresses pulmonary metastasis associated with lung growth. Am. J. Respir. Cell. Mol. Biol. 33, 629–635.
Streck, C. J., Zhou, J., Ng, C. Y., Zhang, Y., Nathwani, A. C., and Davidoff, A. M. (2004) Longterm recombinant adeno-associated, virus-mediated, liver-generated expression of an angiogenesis inhibitor improves survival in mice with disseminated neuroblastoma. J. Am. Coll. Surg. 199, 78–86.
Ferrara, N., Hillan, K. J., Gerber, H. P., and Novotny, W. (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 3, 391–400.
Drevs, J., Hofmann, I., Hugenschmidt, H., Wittig, C., Madjar, H., Muller, M., Wood, J., Martiny-Baron, G., Unger, C., and Marme, D. (2000) Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res. 60, 4819–4824.
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., Ferrara, N., Fyfe, G., Rogers, B., Ross, R., and Kabbinavar, F. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335–2342.
Giantonio, B. J., Catalano, P. J., Meropol, N. J., O'Dwyer, P. J., Mitchell, E. P., Alberts, S. R., Schwartz, M. A., and Benson, A. B., 3rd (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol. 25, 1539–1544.
Cohen, M. H., Gootenberg, J., Keegan, P., and Pazdur, R. (2007) FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. Oncologist 12, 356–361.
Cohen, M. H., Gootenberg, J., Keegan, P., and Pazdur, R. (2007) FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 12, 713–718.
O'Reilly, M. S., Holmgren, L., Chen, C., and Folkman, J. (1996) Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat. Med. 2, 689–692.
Subramanian, I. V., Ghebre, R., and Ramakrishnan, S. (2005) Adeno-associated virus-mediated delivery of a mutant endostatin suppresses ovarian carcinoma growth in mice. Gene Ther. 12, 30–38.
Subramanian, I. V., Bui Nguyen, T. M., Truskinovsky, A. M., Tolar, J., Blazar, B. R., and Ramakrishnan, S. (2006) Adeno-associated virus-mediated delivery of a mutant endostatin in combination with carboplatin treatment inhibits orthotopic growth of ovarian cancer and improves long-term survival. Cancer Res. 66, 4319–4328.
Zhang, X., Xu, J., Lawler, J., Terwilliger, E., and Parangi, S. (2007) Adeno-associated virus-mediated antiangiogenic gene therapy with thrombospondin-1 type 1 repeats and endostatin. Clin. Cancer Res. 13, 3968–3976.
Albini, A., Marchisone, C., Del Grosso, F., Benelli, R., Masiello, L., Tacchetti, C., Bono, M., Ferrantini, M., Rozera, C., Truini, M., Belardelli, F., Santi, L., and Noonan, D. M. (2000) Inhibition of angiogenesis and vascular tumor growth by interferon-producing cells: A gene therapy approach. Am. J. Pathol. 156, 1381–1393.
Sanches, R., Kuiper, M., Penault-Llorca, F., Aunoble, B., D'Incan, C., and Bignon, Y. J. (2000) Antitumoral effect of interleukin-12-secreting fibroblasts in a mouse model of ovarian cancer: implications for the use of ovarian cancer biopsy-derived fibroblasts as a vehicle for regional gene therapy. Cancer Gene Ther. 7, 707–720.
Saleh, M., Jonas, N. K., Wiegmans, A., and Stylli, S. S. (2000) The treatment of established intracranial tumors by in situ retroviral IFN-gamma transfer. Gene Ther. 7, 1715–1724.
Xue, S. A., and Stauss, H. J. (2007) Enhancing immune responses for cancer therapy. Cell. Mol. Immunol. 4, 173–184.
Sobol, R. E. (2006) The rationale for prophylactic cancer vaccines and need for a paradigm shift. Cancer Gene Ther. 13, 725–731.
Thomas, S., Hart, D. P., Xue, S. A., Cesco-Gaspere, M., and Stauss, H. J. (2007) T-cell receptor gene therapy for cancer: the progress to date and future objectives. Expert Opin. Biol. Ther. 7, 1207–1218.
Akbulut, H., Tang, Y., Akbulut, K. G., Maynard, J., Zhang, L., and Deisseroth, A. (2006) Antitumor immune response induced by i.t. injection of vector-activated dendritic cells and chemotherapy suppresses metastatic breast cancer. Mol. Cancer Ther. 5, 1975–1985.
Ribas, A., Butterfield, L. H., Glaspy, J. A., and Economou, J. S. (2003) Current developments in cancer vaccines and cellular immunotherapy. J. Clin. Oncol. 21, 2415–2432.
Vetter, K. M., and Geller, S. E. (2007) Moving forward: human papillomavirus vaccination and the prevention of cervical cancer. J. Womens Health (Larchmt) 16, 1258–1268.
(2007) Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV Infection. J. Infect. Dis. 196, 1438–1446.
Bosch, F. X., Lorincz, A., Munoz, N., Meijer, C. J., and Shah, K. V. (2002) The causal relation between human papillomavirus and cervical cancer. J. Clin. Pathol. 55, 244–265.
Rosenberg, S. A., and Dudley, M. E. (2004) Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc. Natl. Acad. Sci. USA 101(Suppl 2), 14639–14645.
Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., Zheng, Z., Nahvi, A., de Vries, C. R., Rogers-Freezer, L. J., Mavroukakis, S. A., and Rosenberg, S. A. (2006) Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314, 126–129.
Gillet, J. P., Kimchi-Sarfaty, C., Shinar, S., Licht, T., Lee, C., Hafkemeyer, P., Hrycyna, C., Pastan, I., and Gottesman, M. (2008) Selectable markers for gene therapy. In: Templeton, N., ed. Gene and Cell Therapy: Therapeutic Mechanisms and Strategies, 3rd edition. Boca Raton, FL: Taylor & Francis.
Flasshove, M., Banerjee, D., Leonard, J. P., Mineishi, S., Li, M. X., Bertino, J. R., and Moore, M. A. (1998) Retroviral transduction of human CD34 + umbilical cord blood progenitor cells with a mutated dihydrofolate reductase cDNA. Hum. Gene Ther. 9, 63–71.
Wang, G., Weiss, C., Sheng, P., and Bresnick, E. (1996) Retrovirus-mediated transfer of the human O6-methylguanine-DNA methyltransferase gene into a murine hematopoietic stem cell line and resistance to the toxic effects of certain alkylating agents. Biochem. Pharmacol. 51, 1221–1228.
Letourneau, S., Greenbaum, M., and Cournoyer, D. (1996) Retrovirus-mediated gene transfer of rat glutathione S-transferase Yc confers in vitro resistance to alkylating agents in human leukemia cells and in clonogenic mouse hematopoietic progenitor cells. Hum. Gene Ther. 7, 831–840.
Magni, M., Shammah, S., Schiro, R., Mellado, W., Dalla-Favera, R., and Gianni, A. M. (1996) Induction of cyclophosphamide-resistance by aldehyde-dehydrogenase gene transfer. Blood 87, 1097–1103.
Zaboikin, M., Srinivasakumar, N., and Schuening, F. (2006) Gene therapy with drug resistance genes. Cancer Gene Ther. 13, 335–345.
Gottesman, M. M., Hrycyna, C. A., Schoenlein, P. V., Germann, U. A., and Pastan, I. (1995) Genetic analysis of the multidrug transporter. Annu. Rev. Genet. 29, 607–649.
D'Hondt, V., Caruso, M., and Bank, A. (1997) Retrovirus-mediated gene transfer of the multidrug resistance-associated protein (MRP) cDNA protects cells from chemotherapeutic agents. Hum. Gene Ther. 8, 1745–1751.
Ujhelly, O., Ozvegy, C., Varady, G., Cervenak, J., Homolya, L., Grez, M., Scheffer, G., Roos, D., Bates, S. E., Varadi, A., Sarkadi, B., and Nemet, K. (2003) Application of a human multidrug transporter (ABCG2) variant as selectable marker in gene transfer to progenitor cells. Hum. Gene Ther. 14, 403–412.
Szakacs, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., and Gottesman, M. M. (2006) Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 5, 219–234.
Gillet, J. P., Efferth, T., and Remacle, J. (2007) Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochim. Biophys. Acta 1775, 237–262.
Hesdorffer, C., Antman, K., Bank, A., Fetell, M., Mears, G., and Begg, M. (1994) Human MDR gene transfer in patients with advanced cancer. Hum. Gene Ther. 5, 1151–1160.
O'Shaughnessy, J. A., Cowan, K. H., Nienhuis, A. W., McDonagh, K. T., Sorrentino, B. P., Dunbar, C. E., Chiang, Y., Wilson, W., Goldspiel, B., Kohler, D., and et al. (1994) Retroviral mediated transfer of the human multidrug resistance gene (MDR-1) into hematopoietic stem cells during autologous transplantation after intensive chemotherapy for metastatic breast cancer. Hum. Gene Ther. 5, 891–911.
Cowan, K. H., Moscow, J. A., Huang, H., Zujewski, J. A., O'Shaughnessy, J., Sorrentino, B., Hines, K., Carter, C., Schneider, E., Cusack, G., Noone, M., Dunbar, C., Steinberg, S., Wilson, W., Goldspiel, B., Read, E. J., Leitman, S. F., McDonagh, K., Chow, C., Abati, A., Chiang, Y., Chang, Y. N., Gottesman, M. M., Pastan, I., and Nienhuis, A. (1999) Paclitaxel chemotherapy after autologous stem-cell transplantation and engraftment of hematopoietic cells transduced with a retrovirus containing the multidrug resistance complementary DNA (MDR1) in metastatic breast cancer patients. Clin. Cancer Res. 5, 1619–1628.
Hanania, E. G., Giles, R. E., Kavanagh, J., Fu, S. Q., Ellerson, D., Zu, Z., Wang, T., Su, Y., Kudelka, A., Rahman, Z., Holmes, F., Hortobagyi, G., Claxton, D., Bachier, C., Thall, P., Cheng, S., Hester, J., Ostrove, J. M., Bird, R. E., Chang, A., Korbling, M., Seong, D., Cote, R., Holzmayer, T., Deisseroth, A. B., and et al. (1996) Results of MDR-1 vector modification trial indicate that granulocyte/macrophage colony-forming unit cells do not contribute to posttransplant hematopoietic recovery following intensive systemic therapy. Proc. Natl. Acad. Sci. USA 93, 15346–15351.
Hesdorffer, C., Ayello, J., Ward, M., Kaubisch, A., Vahdat, L., Balmaceda, C., Garrett, T., Fetell, M., Reiss, R., Bank, A., and Antman, K. (1998) Phase I trial of retroviral-mediated transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation. J. Clin. Oncol. 16, 165–172.
Gottesman, M. M. (2003) Cancer gene therapy: an awkward adolescence. Cancer Gene Ther. 10, 501–508.
Parker, A. L., Newman, C., Briggs, S., Seymour, L., and Sheridan, P. J. (2003) Nonviral gene delivery: techniques and implications for molecular medicine. Expert Rev. Mol. Med. 5, 1–15.
Berk, A. J. (1986) Adenovirus promoters and E1A transactivation. Annu. Rev. Genet. 20, 45–79.
Roth, J., and Dobbelstein, M. (2003) Interaction of p53 with the adenovirus E1B-55 kDa protein. Methods Mol. Biol. 234, 135–149.
Sundararajan, R., Cuconati, A., Nelson, D., and White, E. (2001) Tumor necrosis factor-alpha induces Bax-Bak interaction and apoptosis, which is inhibited by adenovirus E1B 19K. J. Biol. Chem. 276, 45120–45127.
Kindsmuller, K., Groitl, P., Hartl, B., Blanchette, P., Hauber, J., and Dobner, T. (2007) Intranuclear targeting and nuclear export of the adenovirus E1B-55K protein are regulated by SUMO1 conjugation. Proc. Natl. Acad. Sci. USA 104, 6684–6689.
Wei, M. C., Zong, W. X., Cheng, E. H., Lindsten, T., Panoutsakopoulou, V., Ross, A. J., Roth, K. A., MacGregor, G. R., Thompson, C. B., and Korsmeyer, S. J. (2001) Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 292, 727–730.
Han, J., Goldstein, L. A., Gastman, B. R., Rabinovitz, A., Wang, G. Q., Fang, B., and Rabinowich, H. (2004) Differential involvement of Bax and Bak in TRAIL-mediated apoptosis of leukemic T cells. Leukemia 18, 1671–1680.
Swaminathan, S., and Thimmapaya, B. (1996) Transactivation of adenovirus E2-early promoter by E1A and E4 6/7 in the context of viral chromosome. J. Mol. Biol. 258, 736–746.
Horwitz, M. S. (2001) Adenovirus immunoregulatory genes and their cellular targets. Virology 279, 1–8.
Horwitz, M. S. (2004) Function of adenovirus E3 proteins and their interactions with immunoregulatory cell proteins. J. Gene Med. 6(Suppl 1), S172–183.
Weitzman, M. D. (2005) Functions of the adenovirus E4 proteins and their impact on viral vectors. Front Biosci. 10, 1106–1117.
Peng, K. W., Morling, F. J., Cosset, F. L., Murphy, G., and Russell, S. J. (1997) A gene delivery system activatable by disease-associated matrix metalloproteinases. Hum. Gene Ther. 8, 729–738.
Buchholz, C. J., Peng, K. W., Morling, F. J., Zhang, J., Cosset, F. L., and Russell, S. J. (1998) In vivo selection of protease cleavage sites from retrovirus display libraries. Nat. Biotechnol. 16, 951–954.
Peng, K. W., Vile, R., Cosset, F. L., and Russell, S. (1999) Selective transduction of protease-rich tumors by matrix-metalloproteinase-targeted retroviral vectors. Gene Ther. 6, 1552–1557.
Maurice, M., Mazur, S., Bullough, F. J., Salvetti, A., Collins, M. K., Russell, S. J., and Cosset, F. L. (1999) Efficient gene delivery to quiescent interleukin-2 (IL-2)-dependent cells by murine leukemia virus-derived vectors harboring IL-2 chimeric envelope glycoproteins. Blood 94, 401–410.
Cosset, F. L., Morling, F. J., Takeuchi, Y., Weiss, R. A., Collins, M. K., and Russell, S. J. (1995) Retroviral retargeting by envelopes expressing an N-terminal binding domain. J. Virol. 69, 6314–6322.
Fielding, A. K., Maurice, M., Morling, F. J., Cosset, F. L., and Russell, S. J. (1998) Inverse targeting of retroviral vectors: selective gene transfer in a mixed population of hematopoietic and nonhematopoietic cells. Blood 91, 1802–1809.
Gordon, E. M., Liu, P. X., Chen, Z. H., Liu, L., Whitley, M. D., Gee, C., Groshen, S., Hinton, D. R., Beart, R. W., and Hall, F. L. (2000) Inhibition of metastatic tumor growth in nude mice by portal vein infusions of matrix-targeted retroviral vectors bearing a cytocidal cyclin G1 construct. Cancer Res. 60, 3343–3347.
Hall, F. L., Liu, L., Zhu, N. L., Stapfer, M., Anderson, W. F., Beart, R. W., and Gordon, E. M. (2000) Molecular engineering of matrix-targeted retroviral vectors incorporating a surveillance function inherent in von Willebrand factor. Hum. Gene Ther. 11, 983–993.
Lorimer, I. A., and Lavictoire, S. J. (2000) Targeting retrovirus to cancer cells expressing a mutant EGF receptor by insertion of a single chain antibody variable domain in the envelope glycoprotein receptor binding lobe. J. Immunol. Methods 237, 147–157.
Martin, F., Chowdhury, S., Neil, S., Phillipps, N., and Collins, M. K. (2002) Envelope-targeted retrovirus vectors transduce melanoma xenografts but not spleen or liver. Mol. Ther. 5, 269–274.
Engelstadter, M., Bobkova, M., Baier, M., Stitz, J., Holtkamp, N., Chu, T. H., Kurth, R., Dornburg, R., Buchholz, C. J., and Cichutek, K. (2000) Targeting human T cells by retroviral vectors displaying antibody domains selected from a phage display library. Hum. Gene Ther. 11, 293–303.
Khare, P. D., Shao-Xi, L., Kuroki, M., Hirose, Y., Arakawa, F., Nakamura, K., Tomita, Y., and Kuroki, M. (2001) Specifically targeted killing of carcinoembryonic antigen (CEA)-expressing cells by a retroviral vector displaying single-chain variable fragmented antibody to CEA and carrying the gene for inducible nitric oxide synthase. Cancer Res. 61, 370–375.
Somia, N. V., Miyoshi, H., Schmitt, M. J., and Verma, I. M. (2000) Retroviral vector targeting to human immunodeficiency virus type 1-infected cells by receptor pseudotyping. J. Virol. 74, 4420–4424.
Bittner, A., Mitnacht-Kraus, R., and Schnierle, B. S. (2002) Specific transduction of HIV-1 envelope expressing cells by retroviral vectors pseudotyped with hybrid CD4/CXCR4 receptors. J. Virol. Methods 104, 83–92.
Kimchi-Sarfaty, C., Alexander, N. S., Brittain, S., Ali, S., and Gottesman, M. M. (2004) Transduction of multiple cell types using improved conditions for gene delivery and expression of SV40 pseudovirions packaged in vitro. Biotechniques 37, 270–275.
Oppenheim, A., Peleg, A., Fibach, E., and Rachmilewitz, E. A. (1986) Efficient introduction of plasmid DNA into human hemopoietic cells by encapsidation in simian virus 40 pseudovirions. Proc. Natl. Acad. Sci. USA 83, 6925–6929.
Kimchi-Sarfaty, C., Brittain, S., Garfield, S., Caplen, N. J., Tang, Q., and Gottesman, M. M. (2005) Efficient delivery of RNA interference effectors via in vitro-packaged SV40 pseudovirions. Hum. Gene Ther. 16, 1110–1115.
Kimchi-Sarfaty, C., Arora, M., Sandalon, Z., Oppenheim, A., and Gottesman, M. M. (2003) High cloning capacity of in vitro packaged SV40 vectors with no SV40 virus sequences. Hum. Gene Ther. 14, 167–177.
Vera, M., Prieto, J., Strayer, D. S., and Fortes, P. (2004) Factors influencing the production of recombinant SV40 vectors. Mol. Ther. 10, 780–791.
Strayer, D. S., Lamothe, M., Wei, D., Milano, J., and Kondo, R. (2001) Generation of recombinant SV40 vectors for gene transfer. Methods Mol. Biol. 165, 103–117.
Vera, M., and Fortes, P. (2004) Simian virus-40 as a gene therapy vector. DNA Cell Biol. 23, 271–282.
Grzmil, M., Thelen, P., Hemmerlein, B., Schweyer, S., Voigt, S., Mury, D., and Burfeind, P. (2003) Bax inhibitor-1 is overexpressed in prostate cancer and its specific down-regulation by RNA interference leads to cell death in human prostate carcinoma cells. Am. J. Pathol. 163, 543–552.
Futami, T., Miyagishi, M., Seki, M., and Taira, K. (2002) Induction of apoptosis in HeLa cells with siRNA expression vector targeted against bcl-2. Nucleic Acids Res. Suppl.(2): 251–252.
Yin, J. Q., Gao, J., Shao, R., Tian, W. N., Wang, J., and Wan, Y. (2003) siRNA agents inhibit oncogene expression and attenuate human tumor cell growth. J. Exp. Ther. Oncol. 3, 194–204.
Duxbury, M. S., Ito, H., Benoit, E., Zinner, M. J., Ashley, S. W., and Whang, E. E. (2003) RNA interference targeting focal adhesion kinase enhances pancreatic adenocarcinoma gemcitabine chemosensitivity. Biochem. Biophys. Res. Commun. 311, 786–792.
Sanceau, J., Truchet, S., and Bauvois, B. (2003) Matrix metalloproteinase-9 silencing by RNA interference triggers the migratory-adhesive switch in Ewing's sarcoma cells. J. Biol. Chem. 278, 36537–36546.
Zhang, L., Yang, N., Mohamed-Hadley, A., Rubin, S. C., and Coukos, G. (2003) Vector-based RNAi, a novel tool for isoform-specific knock-down of VEGF and anti-angiogenesis gene therapy of cancer. Biochem. Biophys. Res. Commun. 303, 1169–1178.
De Schrijver, E., Brusselmans, K., Heyns, W., Verhoeven, G., and Swinnen, J. V. (2003) RNA interference-mediated silencing of the fatty acid synthase gene attenuates growth and induces morphological changes and apoptosis of LNCaP prostate cancer cells. Cancer Res. 63, 3799–3804.
Nieth, C., Priebsch, A., Stege, A., and Lage, H. (2003) Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi). FEBS Lett. 545, 144–150.
Lois, C., Refaeli, Y., Qin, X. F., and Van Parijs, L. (2001) Retroviruses as tools to study the immune system. Curr. Opin. Immunol. 13, 496–504.
Spankuch-Schmitt, B., Bereiter-Hahn, J., Kaufmann, M., and Strebhardt, K. (2002) Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells. J. Natl. Cancer Inst. 94, 1863–1877.
Konnikova, L., Kotecki, M., Kruger, M. M., and Cochran, B. H. (2003) Knockdown of STAT3 expression by RNAi induces apoptosis in astrocytoma cells. BMC Cancer 3, 23.
Nagy, P., Arndt-Jovin, D. J., and Jovin, T. M. (2003) Small interfering RNAs suppress the expression of endogenous and GFP-fused epidermal growth factor receptor (erbB1) and induce apoptosis in erbB1-overexpressing cells. Exp Cell Res. 285, 39–49.
Zhang, M., Zhang, X., Bai, C. X., Chen, J., and Wei, M. Q. (2004) Inhibition of epidermal growth factor receptor expression by RNA interference in A549 cells. Acta Pharmacol. Sin. 25, 61–67.
Butz, K., Ristriani, T., Hengstermann, A., Denk, C., Scheffner, M., and Hoppe-Seyler, F. (2003) siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells. Oncogene 22, 5938–5945.
Li, X. P., Li, G., Peng, Y., Kung, H. F., and Lin, M. C. (2004) Suppression of Epstein-Barr virus-encoded latent membrane protein-1 by RNA interference inhibits the metastatic potential of nasopharyngeal carcinoma cells. Biochem. Biophys. Res. Commun. 315, 212–218.
Wilda, M., Fuchs, U., Wossmann, W., and Borkhardt, A. (2002) Killing of leukemic cells with a BCR/ABL fusion gene by RNA interference (RNAi). Oncogene 21, 5716–5724.
Wohlbold, L., van der Kuip, H., Miething, C., Vornlocher, H. P., Knabbe, C., Duyster, J., and Aulitzky, W. E. (2003) Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571). Blood 102, 2236–2239.
Kosciolek, B. A., Kalantidis, K., Tabler, M., and Rowley, P. T. (2003) Inhibition of telomerase activity in human cancer cells by RNA interference. Mol. Cancer Ther. 2, 209–216.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Humana Press, a part of Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Gillet, JP., Macadangdang, B., Fathke, R., Gottesman, M., Kimchi-Sarfaty, C. (2009). The Development of Gene Therapy: From Monogenic Recessive Disorders to Complex Diseases Such as Cancer. In: Walther, W., Stein, U. (eds) Gene Therapy of Cancer. Methods in Molecular Biology™, vol 542. Humana Press. https://doi.org/10.1007/978-1-59745-561-9_1
Download citation
DOI: https://doi.org/10.1007/978-1-59745-561-9_1
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-934115-85-5
Online ISBN: 978-1-59745-561-9
eBook Packages: Springer Protocols